October 19 (Thu) 10:00-12:00 ROOM 323 |
|
Chair: Sunghoi Hong (Korea University) | |
10:00-10:30 |
![]() Gene therapeutics via ribozyme-based RNA editing technology
Seong-Wook Lee
Dankook University / Rznomics Inc., Korea
|
---|---|
10:30-11:00 |
![]() Targeting synapse as a common pathology in neurological diseases from the perspective of FAM19A5 and its monoclonal antibody.
Joseph Park
Clinical Development, Neuracle Science Co., Ltd., Korea
|
11:00-11:30 |
![]() From Lab to Clinic: A Comprehensive Guide to Developing iPS Cell-Derived Therapies
Yoojun Nam
YiPSCELL, Korea
|
11:30-12:00 |
![]() The Present and Future of Korea's Bio Industry
Soo-Jin Choi
Tech University of Korea, Korea
|
October 19 (Thu) 10:00-12:00 ROOM 321-322 |
|
Chair: KilSoo Kim (Preclinical Research Center, K-MEDI hub PRC) Un-Kyung Kim (Kyungpook National University) |
|
10:00-10:30 |
![]() Discovery of DN203368, a dual inverse agonist regulating estrogen-related receptor beta and gamma (ERR¥â/¥ã), as a novel orally active anticancer agent against colorectal cancer
Yong Hyun Jeon
Preclinical Research Center, K-MEDI hub PRC, Korea
|
---|---|
10:30-11:00 |
![]() Targeting Hippo-YAP-TEAD Signaling Pathway for Therapeutic Intervention
Boksik Cha
New Drug Development Center, K-MEDI hub, Korea
|
11:00-11:30 |
![]() ETN101 inhibits tumor growth of hepatocellular carcinoma through multitargeted inhibition of receptor tyrosine kinases
Garam Choi
Etnova Therapeutics Corp., Korea
|
11:30-12:00 |
![]() Non-clinical development of AAV9 gene therapy products delivering Nurr1 and Foxa2 genes for therapeutic approach to Alzheimer's Disease
Seonghoon Lee
Innopeutics Corporation, Korea
|